Q2 2024 Predictive Oncology Inc Earnings Call Transcript
Key Points
- Predictive Oncology Inc (POAI) successfully completed a multiyear ovarian cancer study with UPMC Magee-Womens Hospital, enhancing their AI and machine learning capabilities for biomarker discovery.
- The company launched a novel organ-specific 3D cell culture technology, which offers more accurate predictions of clinical outcomes and reduces the need for animal testing.
- The ACE initiative with the University of Michigan marks Predictive Oncology Inc's entry into true drug discovery, expanding their capabilities in small and large molecule models.
- A strategic cost reduction initiative is expected to reduce cash burn by approximately $2.5 million annually, improving financial efficiency.
- Recent capital raises totaling $5.0 million have bolstered the company's cash position, extending their financial runway.
- Revenues for the second quarter of 2024 decreased to $279,000 from $490,000 in the same period of 2023, indicating a decline in sales performance.
- The company reported a net loss per share of $0.68 for the second quarter of 2024, although this is an improvement from $0.98 in the previous year.
- The Birmingham operations, which were consolidated into Pittsburgh, generated net losses and minimal revenue, highlighting challenges in profitability.
- Predictive Oncology Inc's accumulated deficit increased to $175 million as of June 30, 2024, up from $168 million at the end of 2023.
- Despite cost reductions, the company still used $6.6 million in operating activities for the first half of 2024, reflecting ongoing financial challenges.
Good day, and thank you for standing by. Welcome to the Predictive Oncology Second Quarter 2024 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the call over to your speaker, Mr. Glenn Garmont, Investor Relations. Thank you. You may begin.
Welcome, and thank you, everyone, for dialing into the Predictive Oncology Second Quarter 2024 Financial Results Call. First, you'll hear from our Chief Executive Officer and Chairman of the Board, Raymond Vennare; and our Chief Financial Officer, Josh Blacher, who will review our financials.
Certain matters discussed on this call contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements other than statements of historical facts included in the call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
